Detalhe da pesquisa
1.
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
PLoS Med
; 16(4): e1002790, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31039172
2.
Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity.
J Infect Dis
; 213(5): 824-30, 2016 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26450421
3.
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial.
Lancet Infect Dis
; 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621405
4.
Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults.
Vaccines (Basel)
; 9(4)2021 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33923628
5.
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Vaccine
; 38(4): 779-789, 2020 01 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31735500
6.
VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy.
F1000Res
; 7: 485, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29904595
7.
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A.
Wellcome Open Res
; 3: 121, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30687792
8.
The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
PLoS Negl Trop Dis
; 11(5): e0005440, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28472067
9.
A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
Vaccine
; 34(11): 1412-21, 2016 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26854906
10.
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
PLoS One
; 10(11): e0141687, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26529238
11.
The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
PLoS One
; 9(2): e87340, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24498312
12.
Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
PLoS One
; 8(6): e67177, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23840618